Hexapeptide-11
/ Synthetic hexapeptide; INCI 'Hexapeptide-11'; anti-senescence cosmetic peptideALIAS · Peptamide 6 (trade) · Hexapeptide-11 (INCI) · Anti-senescence hexapeptide
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4 cosmeceutical. INCI catalog peptide marketed under the Peptamide 6 trade name; mechanism positioning is fibroblast anti-senescence. Yeast-fermentation-derived hexapeptide. PubMed-indexed independent primary literature is essentially absent; supplier materials provide the published narrative.
The supplier-stated mechanism is reduction of senescence-associated markers (SA-β-gal positivity, senescence-associated secretory phenotype components) in cultured human dermal fibroblasts, with downstream positioning as a topical anti-aging cosmetic peptide. The bridge from in-vitro fibroblast senescence rescue to topical cosmetic effect on human skin is the central translational gap. Senescence biology has become a credible geroscience target; whether a six-residue peptide applied topically engages that biology in intact dermis is unverified outside supplier reports.
None substantive in the indexed primary literature. Supplier in-vitro fibroblast senescence assays are referenced in INCI documentation but are not represented as PubMed-indexed peer-reviewed papers.
No formal human safety database in indexed literature. Topical cosmetic application is generally well tolerated.
Regulatory status
- FDA status:
- Not FDA-approved
The 'anti-senescence' framing borrows credibility from the geroscience literature on senolytics and SASP modulation without evidence that a topical hexapeptide acts via those pathways in human skin. Vendor positioning conflates emerging geroscience concepts with cosmetic-peptide marketing.